TScan Therapeutics (TCRX) Market Capitalization (2021 - 2026)

TScan Therapeutics (TCRX) has reported Market Capitalization for 6 consecutive years, with $127.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Market Capitalization fell 32.3% year-over-year to $127.3 million in Q2 2026; TTM through Jun 2026 was $127.3 million, a 32.3% decrease from a year earlier, with the FY2025 full-year figure at $129.8 million, down 61.88% from the prior year.
• Market Capitalization was $127.3 million for Q2 2026 at TScan Therapeutics, down from $131.2 million in the prior quarter.
• Over five years, Market Capitalization peaked at $753.3 million in Q1 2024 and troughed at $37.3 million in Q4 2022.
• A 5-year average of $243.8 million and a median of $155.1 million in 2025 frame the typical range for Market Capitalization.
• Across the five-year window, Market Capitalization soared 1380.73% in 2024 and sank 76.24% in 2025, its largest moves.
• Over 5 years, Market Capitalization stood at $37.3 million in 2022, then soared by 926.02% to $382.4 million in 2023, then retreated by 10.98% to $340.5 million in 2024, then sank by 61.88% to $129.8 million in 2025, then declined by 1.87% to $127.3 million in 2026.
• The last three Market Capitalization figures came in at $127.3 million (Q2 2026), $131.2 million (Q1 2026), and $129.8 million (Q4 2025), per Business Quant data.